Truist analyst Srikripa Devarakonda raised the firm’s price target on Cytokinetics (CYTK) to $92 from $84 and keeps a Buy rating on the shares. Ahead of Q4 results, the firm is updating its modeling to incorporate Myqorzo $108,400 / annual WAC price, the effects of Myqorzo’s free drug program, and what will be an increase in 2026 OpEx to fund near-term operations, the analyst tells investors in a research note.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK: